The IMspire150 study randomized 514 treatment-naïve patients with V600 BRAF mutated unresectable stage III/IV melanoma to treatment with vemurafenib and cobimetinib (V/C) plus or minus the PD-L1 inhibitor atezolizumab. Here, BRAF is linked to melanoma.